Application of tsRNA as molecular marker for diagnosing primary open-angle glaucoma
By using tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC as molecular markers, combined with Pandora sequencing and kit technology, the problem of early diagnosis of primary open-angle glaucoma was solved and a high diagnostic accuracy was achieved.
Patent Information
- Application Number
- CN202510847579.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-24
- Publication Date
- 2025-09-26
- Estimated Expiration
- 2045-06-24
AI Technical Summary
Existing technologies make it difficult to diagnose primary open-angle glaucoma early. Current ophthalmic imaging technology can usually only detect the disease after obvious loss of retinal ganglion cells, making diagnosis difficult.
tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC were used as molecular markers, and the tsRNAs expression profiles in PBMCs of patients and healthy controls were analyzed by Pandora sequencing. It was found that tsRNA-5009b-ValCAC expression was downregulated in POAG patients, and a corresponding kit was developed for early diagnosis.
By downregulating the expression of tsRNA-5009b-ValCAC, early diagnosis of POAG was achieved, and the AUC value of the ROC curve was 0.717, showing good diagnostic performance.
Smart Images

Figure CN120700133A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological detection, and in particular to a molecular marker for diagnosing primary open-angle glaucoma and an application thereof. Background Art
[0002] Glaucoma, an eye disease characterized by the progressive degeneration of retinal ganglion cells (RGCs), is the leading cause of irreversible vision loss worldwide. According to the World Health Organization (WHO), the global prevalence of glaucoma exceeds 80 million cases. This number is expected to increase to 110 million by 2040, particularly affecting the aging population. Among the various types of glaucoma, primary open-angle glaucoma (POAG) is the most common, accounting for over 70% of all cases.
[0003] Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy characterized by elevated intraocular pressure and morphological changes in the optic disc and retinal nerve fiber layer, without the presence of other eye diseases or congenital abnormalities. POAG is common and increases in incidence with age. Due to its insidious onset, POAG is difficult to diagnose; current ophthalmic imaging techniques typically detect the disease only after significant loss of retinal ganglion cells (RGCs).
[0004] Recent advances in high-throughput sequencing technologies have greatly expanded the scope of small noncoding RNAs (sncRNAs), including microRNAs (miRNAs), piwi-interacting RNAs (piRNAs), small interfering RNAs (siRNAs), and tRNA-derived small RNAs (tsRNAs). SncRNAs, defined as noncoding RNAs shorter than 200 nucleotides, are increasingly recognized for their key roles in gene regulation and disease pathogenesis. Emerging evidence suggests that dysregulation of sncRNAs plays a key role in a variety of diseases, including cancer, cardiovascular disease, immune dysfunction, and neurodegenerative diseases. Emerging dual markers in liquid biopsies, particularly miRNAs (such as miR-143-3p and miR-27a-3p), have been shown to have potential for glaucoma diagnosis. However, the diagnostic functions of other classes of sncRNAs, including piRNAs and tsRNAs, remain largely unexplored.
[0005] tsRNAs have emerged as a new class of regulatory molecules with potential relevance to neurodegenerative diseases. tRF-5, derived from precise cleavage of the 5' end of mature tRNA, has been implicated as a key regulator of diverse biological processes, including protein translation, cellular metabolism, and epigenetic regulation. tRF-5 (e.g., tRF5-GlyGCC and tRF5-GluCTC) have been reported to be upregulated in Alzheimer's disease, and NSun2 deficiency-induced accumulation of 5'-tRFs in neurons triggers stress responses and apoptosis, highlighting their potential neurobiological relevance.
[0006] So far, there are no reports on the use of tsRNA as a molecular marker for the diagnosis of primary open-angle glaucoma. Summary of the Invention
[0007] To solve the above technical problems, the present invention includes the following aspects:
[0008] A first aspect of the present invention provides a molecular marker for early diagnosis of glaucoma, wherein the molecular marker is tsRNA.
[0009] Preferably, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC (SEQ ID NO.3), tsRNA-5016c-CysGCA (SEQ ID NO.4), tsRNA-5003c-GlyGCC (SEQ ID NO.5), tsRNA-3017a-ValTAC (SEQ ID NO.6), tsRNA-5026b-ValAAC (SEQ ID NO.7), tsRNA-5023b-LeuCAG (SEQ ID NO.8), tsRNA-5009c-ValCAC (SEQ ID NO.9), tsRNA-5030c-GluCTC (SEQ ID NO.10) and tsRNA-5003c-GlyGCC (SEQ ID NO.11).
[0010] Preferably, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC (SEQ ID NO. 3) and tsRNA-5003c-GlyGCC (SEQ ID NO. 11).
[0011] More preferably, the tsRNA is tsRNA-5009b-ValCAC (SEQ ID NO. 3).
[0012] Preferably, the glaucoma is primary open-angle glaucoma.
[0013] A second aspect of the present invention provides a kit for early diagnosis of glaucoma, wherein the kit comprises a reagent for detecting the level of a molecular marker in a sample to be tested, wherein the molecular marker is tsRNA.
[0014] Preferably, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC (SEQ ID NO.3), tsRNA-5016c-CysGCA (SEQ ID NO.4), tsRNA-5003c-GlyGCC (SEQ ID NO.5), tsRNA-3017a-ValTAC (SEQ ID NO.6), tsRNA-5026b-ValAAC (SEQ ID NO.7), tsRNA-5023b-LeuCAG (SEQ ID NO.8), tsRNA-5009c-ValCAC (SEQ ID NO.9), tsRNA-5030c-GluCTC (SEQ ID NO.10) and tsRNA-5003c-GlyGCC (SEQ ID NO.11).
[0015] Preferably, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC (SEQ ID NO. 3) and tsRNA-5003c-GlyGCC (SEQ ID NO. 11).
[0016] More preferably, the tsRNA is tsRNA-5009b-ValCAC (SEQ ID NO. 3).
[0017] Preferably, the glaucoma is primary open-angle glaucoma.
[0018] Preferably, the reagent includes a tsRNA gene-specific forward primer and a reverse primer, the sequence of the forward primer is shown in SEQ ID NO.1, and the reverse primer is a universal reverse primer from the miRNA first-strand cDNA synthesis kit (tailing method), which is purchased from Sangon Biotech (Shanghai) Co., Ltd.
[0019] Preferably, the reagent includes a tsRNA gene-specific forward primer and a reverse primer, the sequence of the forward primer is shown in SEQ ID NO.2, and the reverse primer is a universal reverse primer from the miRNA first-strand cDNA synthesis kit (tailing method), which is purchased from Sangon Biotech (Shanghai) Co., Ltd.
[0020] Preferably, the sample to be tested is selected from one or more of the subject's tissue, whole blood, plasma, serum, saliva, sputum, pleural effusion, bronchoalveolar lavage fluid, and urine. More preferably, the sample to be tested is selected from one or more of the subject's whole blood, plasma, and serum.
[0021] Preferably, the subject is a mammal, and more preferably, the subject is a human.
[0022] A third aspect of the present invention provides use of a reagent for detecting tsRNA in preparing a kit for early diagnosis of glaucoma.
[0023] Preferably, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC (SEQ ID NO.3), tsRNA-5016c-CysGCA (SEQ ID NO.4), tsRNA-5003c-GlyGCC (SEQ ID NO.5), tsRNA-3017a-ValTAC (SEQ ID NO.6), tsRNA-5026b-ValAAC (SEQ ID NO.7), tsRNA-5023b-LeuCAG (SEQ ID NO.8), tsRNA-5009c-ValCAC (SEQ ID NO.9), tsRNA-5030c-GluCTC (SEQ ID NO.10) and tsRNA-5003c-GlyGCC (SEQ ID NO.11).
[0024] Preferably, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC (SEQ ID NO. 3) and tsRNA-5003c-GlyGCC (SEQ ID NO. 11).
[0025] More preferably, the tsRNA is tsRNA-5009b-ValCAC (SEQ ID NO. 3).
[0026] Preferably, the glaucoma is primary open-angle glaucoma.
[0027] Preferably, the reagent for detecting tsRNA includes a tsRNA gene-specific forward primer and a reverse primer, the sequence of the forward primer is shown in SEQ ID NO.1, and the reverse primer is a universal reverse primer from the miRNA first-strand cDNA synthesis kit (tailing method), which is purchased from Sangon Biotech (Shanghai) Co., Ltd.
[0028] Preferably, the reagent for detecting tsRNA includes a tsRNA gene-specific forward primer and a reverse primer, the sequence of the forward primer is shown in SEQ ID NO. 2, and the reverse primer is a universal reverse primer from the miRNA first-strand cDNA synthesis kit (tailing method), which is purchased from Sangon Biotech (Shanghai) Co., Ltd.
[0029] The technical effects produced by the present invention are:
[0030] The present invention systematically analyzed the expression profiles of tsRNAs in PBMCs of POAG patients and healthy controls using Pandora sequencing, finding that multiple tsRNAs in POAG patients showed significant changes compared to healthy controls. Further qRT-PCR analysis of two of these DE tsRNAs in the validation set revealed downregulation of tsRNA-5009b-ValCAC expression in the POAG group (p < 0.05). The AUC value of tsRNA-5009b-ValCAC in the receiver operating characteristic (ROC) curve was 0.717, demonstrating good diagnostic performance, indicating that these tsRNAs can be used clinically as molecular markers for the early diagnosis of POAG. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Heat map of differentially expressed tsRNAs in POAG;
[0032] Figure 2 Functional enrichment analysis of target genes associated with DE sncRNAs in POAG, including Figure 2 A GO circle diagram shows the enriched biological processes, molecular functions, and cellular components of the target genes corresponding to the differentially expressed tsRNAs. Figure 2 B KEGG bar chart showing the top 10 enriched target gene pathways associated with differentially expressed tsRNAs;
[0033] Figure 3 qRT-PCR validation results of selected snRNAs in healthy controls and POAG patients, including Figure 3 A is the expression level of tsRNA-5009b-ValCAC, Figure 3 B shows the expression level of tsRNA-5003c-GlyGCC (data are expressed as mean ± SEM, * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001).
[0034] Figure 4 ROC curve analysis of tsRNA-5009b-ValCAC in diagnosing POAG. DETAILED DESCRIPTION
[0035] The present invention will be further described below with reference to the examples, but the embodiments of the present invention are not limited thereto. The experimental methods used in the following examples are conventional methods unless otherwise specified.
[0036] Experimental Example 1: Study on tsRNAs Biomarkers for Early Diagnosis of Primary Open-Angle Glaucoma
[0037] 1. Test method
[0038] 1.1 Patients and samples
[0039] All POAG patients and healthy controls were recruited at the Affiliated People's Hospital of Ningbo University from May 2024 to February 2025. This study was approved by the Ethics Committee of the Affiliated People's Hospital of Ningbo University, and all participants provided written informed consent in accordance with the principles of the Declaration of Helsinki. A total of 10 POAG patients and 10 healthy controls were selected for Pandora sequencing, and the validation cohort included 30 POAG patients and 30 healthy controls. Each participant provided 5 ml of peripheral blood for testing. All enrolled participants underwent a comprehensive ophthalmological examination and detailed medical history analysis. Ophthalmological examinations included best corrected visual acuity testing, IOP measurement, gonioscopy, slit lamp examination, fundus examination, visual field testing, optical coherence tomography, and OCTA analysis.
[0040] POAG was diagnosed by experienced glaucoma specialists based on the following criteria: (1) an open anterior chamber angle confirmed by gonioscopy; (2) secondary causes of glaucoma, including pigment dispersion, pseudodetachment, or other anterior segment abnormalities; and (3) evidence of glaucomatous optic nerve head damage, such as increased cup-to-disc ratio, thinning of the neuroretinal margin, notches, or localized retinal nerve fiber layer defects, with or without corresponding visual field loss. To exclude normal-tension glaucoma, patients with POAG had an untreated intraocular pressure exceeding 21 mmHg. All samples were obtained from participants without significant comorbid systemic diseases (e.g., diabetes, cancer, chronic obstructive pulmonary disease) and a history of other major ocular diseases (excluding glaucoma and cataracts). The clinical data of the subjects are shown in Table 1.
[0041] Table 1 Baseline demographic and clinical characteristics of POAG patients and healthy controls in the validation cohort
[0042]
[0043] Note: 1 Pearson χ2 test; 2 Independent samples t-test; 3 Mann-Whitney U test, corrected for continuity; 4Independent-sample t-test, adjusted for variance. IOP: intraocular pressure; BCVA, best-corrected visual acuity; ACD, anterior chamber depth; CCT, central corneal thickness; AL: axial length; POAG, primary open-angle glaucoma; HC, healthy controls.
[0044] 1.2 PBMC cell isolation
[0045] PBMCs were isolated from 5 ml of whole blood using density gradient centrifugation. The blood was diluted with an equal volume of PBS and layered onto Fi-coll-Paque (Cytiva, USA). After centrifugation at 1500 rpm for 40 minutes, the PBMC layer at the interface was collected. The cells were washed twice with PBS and resuspended in 1 ml of Trizol (Thermo Fisher Scientific, USA). The isolated PBMCs were stored at -80°C until use.
[0046] 1.3 Pandora sequencing and data analysis
[0047] PANDORA-seq (Panoramic RNA Display by Overcoming RNA Modification Aborted Sequencing) and raw data analysis were performed by Guangzhou Epigenetic Biotechnology Co., Ltd. T4 polynucleotide kinase was used to convert 3'-P and 2',3'-cP to 3'-OH and add 5'-P. AlkB was used to remove specific RNA methylation modifications. RNA sequences of 15-45 nucleotides were then annotated using SPORTS 1.1 software. The reference database was the tsRNA database tRFdb.
[0048] RNA expression levels of the samples were normalized using TPM. Differentially expressed genes were then identified using the DEGseq R package based on fold change and P value (fold change ≥ 1, P < 0.05). Furthermore, target gene prediction algorithms (miRanda and RNAhybrid) were used to predict microRNA regulatory targets. The target genes were further analyzed for enrichment in KEGG and GO pathways.
[0049] 1.4. sncRNA extraction and reverse transcription real-time PCR (qRT-PCR)
[0050] Total RNA was extracted from PBMC cells using Trizol and analyzed using Thermo Scientific TM μDrop TMThe RNA concentration and purity were determined by plate analysis (Thermo Fisher Scientific, USA) and Thermo Scientific Varioskan LUX (Thermo Fisher Scientific, USA). The template RNA was then reverse transcribed into cDNA using the miRNA First Strand cDNA Synthesis Kit (Tailoring Method) (Shanghai Biotech Co., Ltd.) according to the manufacturer's instructions. The resulting cDNA was then mixed with Taq Pro Universal SYBR qPCR Master Mix (Vazyme) and analyzed using Thermo Scientific Varioskan LUX for real-time fluorescence quantitative PCR. 2 -ΔΔCT Methods: The expression levels of relevant sncRNAs were calculated, using U6 as an internal reference gene. Reverse primers for U6 and sncRNAs were universal reverse primers from the miRNA First-Strand cDNA Synthesis Kit (Tailering Method) (Sangon Biotech (Shanghai) Co., Ltd.). sncRNA gene-specific forward primers were synthesized by Shanghai Bioengineering Company, and their sequences are shown in the table below.
[0051]
[0052] 1.5.Statis4.5 statistical analysis
[0053] Statistical analysis was performed using GraphPad Prism 9 and SPSS 26.0. Normally distributed data are expressed as mean ± standard deviation (mean ± SD), and intergroup comparisons were performed using the independent sample t-test. Data that did not conform to a normal distribution were expressed as median and interquartile range (M(Q1, Q3)), and intergroup comparisons were performed using the Mann-Whitney U test. Unordered categorical data between groups were compared using the Fisher exact test. A p-value < 0.05 was considered statistically significant.
[0054] 2. Test results
[0055] 2.1 Differential expression of tsRNAs in POAG patients
[0056] Based on the threshold of |log2FC| ≥ 1 and p < 0.05, the differential expression of small non-coding RNAs (sncRNAs) was screened, and 9 tsRNAs with high expression levels were identified (Table 2). The heat map of differentially expressed tsRNAs showed that there was a clear clustering between POAG and control samples ( Figure 1 ).
[0057] Table 2 Differentially expressed tsRNA sequences
[0058]
[0059] 2.2 Functional enrichment analysis of DE sncRNAs
[0060] In order to reveal the biological functions of DE sncRNAs target genes, GO and KEGG pathway enrichment analysis was performed in this study. The results showed that the target genes of tsRNA were significantly enriched in biological processes (BP), cellular components (CC), and molecular functions (MF). Specifically, the target genes of tsRNA were enriched in magnesium ion homeostasis (BP), hemoglobin complex (CC), and endodeoxyribonuclease activity (MF) ( Figure 2 A). In addition, KEGG pathway analysis showed that the enriched pathways mainly included propionate metabolism pathway, glycine, serine and threonine metabolism pathway, valine, leucine and isoleucine biosynthesis pathway ( Figure 2 B).
[0061] 2.3 qRT-PCR validation of DE sncRNAs in POAG
[0062] To validate the results of the aforementioned screening test, tsRNAs with sequence differences were screened based on the thresholds of |log2FC| ≥ 1 and p < 0.05. Two tsRNAs (tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC) were selected from the tsRNA sequences with higher expression levels for qRT-PCR analysis in the validation set, which included 30 controls and 30 POAG patients. The qRT-PCR results showed that the expression of tsRNA-5009b-ValCAC (p < 0.05) was downregulated in the POAG group, which was consistent with the sequencing results ( Figure 3 A), while the expression of tsRNA-5003c-GlyGCC (p=0.3611) had no significant difference between the two groups ( Figure 3 B).
[0063] 2.4 ROC curve analysis and diagnostic efficacy evaluation
[0064] To further evaluate the potential of these sncRNAs as diagnostic markers for POAG, receiver operating characteristic (ROC) curves were drawn and the area under the curve (AUC) was calculated. The results showed that the AUC value of tsRNA-5009b-ValCAC was 0.717, with good diagnostic performance ( Figure 4 ).
[0065] Although specific embodiments of the present invention have been described, it will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the scope or spirit of the present invention. Therefore, the present invention is intended to cover all such changes and modifications that fall within the scope of the appended claims and their equivalents.
Claims
1. A molecular marker for early diagnosis of glaucoma, characterized in that: The molecular marker is tsRNA.
2. The molecular marker according to claim 1, characterized in that The tsRNA is selected from one or more of tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC.
3. The molecular marker according to claim 2, characterized in that The tsRNA is tsRNA-5009b-ValCAC.
4. The molecular marker according to claim 3, characterized in that The glaucoma is primary open-angle glaucoma.
5. A kit for early diagnosis of glaucoma, characterized in that: The kit contains a reagent for detecting the level of a molecular marker in a sample to be tested, and the molecular marker is tsRNA.
6. The kit according to claim 5, characterized in that The tsRNA is selected from one or more of tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC.
7. The kit according to claim 6, characterized in that The tsRNA is tsRNA-5009b-ValCAC.
8. Use of a reagent for detecting tsRNA in the preparation of a kit for early diagnosis of glaucoma, characterized in that: The tsRNA is selected from one or more of tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC.
9. The use according to claim 8, characterized in that The tsRNA is tsRNA-5009b-ValCAC.
10. The use according to claim 9, characterized in that The glaucoma is primary open-angle glaucoma.
Citation Information
Patent Citations
Application of plasma / serum exosome hsa-miRNA-29-3p as diagnostic marker for glaucoma
CN109762883A
Application of tRF-54: 75-Ala-AGC-2-M2 as marker and retinopathy diagnosis product for premature infants
CN116814760A
